TrialDiabetes, obesity & metabolism2019

Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes.

Clifford J Bailey et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.